BSE Live
Feb 02, 16:01Prev. Close
1939.35
Open Price
1939.35
Bid Price (Qty.)
1900.00 (13)
Offer Price (Qty.)
1950.00 (110)
NSE Live
Feb 02, 15:54Prev. Close
1940.00
Open Price
1935.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1920.40 (160)
| Balance Sheet of Glenmark Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 0.00 | 25.05 | 24.87 | 24.01 | 23.74 | |
| Total Share Capital | 0.00 | 25.05 | 24.87 | 24.01 | 43.74 | |
| Reserves and Surplus | 0.00 | 1,573.10 | 1,493.00 | 662.35 | 349.36 | |
| Total Reserves and Surplus | 0.00 | 1,573.10 | 1,493.00 | 662.35 | 349.36 | |
| Total Shareholders Funds | 0.00 | 1,598.16 | 1,517.87 | 686.37 | 393.11 | |
| Minority Interest | 0.00 | 3.16 | 1.48 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 280.09 | 245.19 | 458.86 | 525.51 | |
| Deferred Tax Liabilities [Net] | 0.00 | 105.47 | 114.55 | 81.27 | 49.99 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 0.00 | 385.57 | 359.74 | 540.13 | 575.51 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.00 | 1,809.67 | 742.68 | 476.58 | 209.26 | |
| Trade Payables | 0.00 | 343.48 | 230.79 | 160.15 | 108.32 | |
| Other Current Liabilities | 0.00 | 101.00 | 75.24 | 73.44 | 64.25 | |
| Short Term Provisions | 0.00 | 16.44 | 17.76 | 7.18 | 0.81 | |
| Total Current Liabilities | 0.00 | 2,270.58 | 1,066.47 | 717.36 | 382.64 | |
| Total Capital And Liabilities | 0.00 | 4,257.46 | 2,945.56 | 1,943.86 | 1,351.26 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 0.00 | 648.08 | 396.63 | 256.54 | 232.80 | |
| Intangible Assets | 0.00 | 918.16 | 521.88 | 336.31 | 290.01 | |
| Capital Work-In-Progress | 0.00 | 545.41 | 337.23 | 217.57 | 57.65 | |
| Fixed Assets | 0.00 | 2,111.65 | 1,255.74 | 810.43 | 580.47 | |
| Non-Current Investments | 0.00 | 18.12 | 18.82 | 18.72 | 19.70 | |
| Deferred Tax Assets [Net] | 0.00 | 48.55 | 20.00 | 9.27 | 8.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 1.61 | |
| Total Non-Current Assets | 0.00 | 2,178.32 | 1,294.56 | 838.42 | 609.77 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 0.00 | 630.23 | 400.74 | 269.71 | 157.53 | |
| Trade Receivables | 0.00 | 955.34 | 806.85 | 565.97 | 381.59 | |
| Cash And Cash Equivalents | 0.00 | 71.48 | 156.51 | 105.75 | 105.60 | |
| Short Term Loans And Advances | 0.00 | 422.09 | 286.90 | 164.00 | 96.76 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 0.00 | 2,079.14 | 1,651.00 | 1,105.43 | 741.48 | |
| Total Assets | 0.00 | 4,257.46 | 2,945.56 | 1,943.86 | 1,351.26 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 0.00 | 141.09 | 119.16 | 127.74 | 8.01 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 0.00 | 15.84 | 15.84 | 15.84 | 15.84 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 2.06 | 1.37 | 1.10 | |
| Non-Current Investments Unquoted Book Value | 0.00 | 18.08 | 18.77 | 18.68 | 19.61 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015